4D Molecular Therapeutics, Inc. Stock Analysis & AI Score
4D Molecular Therapeutics, Inc. (FDMT) has an ST Score of 51.7 (C+), driven by its Forecast (A) and held back by its Growth (F). Analysts rate it Buy with a $26.00 price target (+76.8% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
4D Molecular Therapeutics, Inc. (FDMT) has an ST Score of 51.7 (C+), driven by its Forecast (A) and held back by its Growth (F). Analysts rate it Buy with a $26.00 price target (+76.8% upside).
- Strongest
- ForecastA
- Weakest
- GrowthF
All factor grades
- ForecastA
- MomentumB+
- ValuationB
- ProfitabilityB-
- Financial StrengthC+
- GrowthF
- Piotroski3/9
Contact
FDMT stock: frequently asked questions
What is FDMT's ST Score?
4D Molecular Therapeutics, Inc. (FDMT) has an ST Score of 51.7 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is FDMT a buy, hold, or sell?
Analysts rate FDMT a Buy, with a price target of $26.00 (+76.8% vs the current price). Our ST Score grades it C+ (51.7/100). The ST Score is a data-driven signal, not a recommendation.
What are FDMT's factor grades?
Valuation B, Profitability B-, Financial Strength C+, Momentum B+, Growth F, Forecast A.
What is FDMT's valuation grade?
4D Molecular Therapeutics, Inc. (FDMT) earns a valuation grade of B, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is FDMT's growth grade?
4D Molecular Therapeutics, Inc. (FDMT) earns a growth grade of F, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is FDMT's profitability grade?
4D Molecular Therapeutics, Inc. (FDMT) earns a profitability grade of B-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is FDMT's financial strength grade?
4D Molecular Therapeutics, Inc. (FDMT) earns a financial strength grade of C+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for FDMT?
The average analyst price target for 4D Molecular Therapeutics, Inc. (FDMT) is $26.00 from 14 analysts, which is +76.8% versus the recent price of $14.71.
What is FDMT's Piotroski score?
4D Molecular Therapeutics, Inc. (FDMT) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.